Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT05116189 |
Title | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) |
Recruitment | Recruiting |
Gender | female |
Phase | Phase III |
Variant Requirements | No |
Sponsors | Merck Sharp & Dohme Corp. |
Indications | |
Therapies |
Bevacizumab + Paclitaxel + Pembrolizumab |
Age Groups: | adult | senior |
Covered Countries | USA | ITA | FRA | DEU | CAN |